Form 4: Artiva Biotherapeutics CEO Sells Shares
Insider Transaction (Form 4)
Fred Aslan, Chief Executive Officer and a Director of Artiva Biotherapeutics, Inc., sold 61,888 shares of common stock on September 3, 2026 for $11.16 per share.
Summary
- Open-market sale: disposed of 61,888 Common Stock at $11.16 ($690,392) on September 3, 2026; holds 1,473,194 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $690,392 of stock on the open market.
Insider Transactions
Fred Aslan — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-03 | Open-market sale | Common Stock | 61,888 | $11 | $690.4K | 1,473,194 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-03 | Open-market sale (61,888 shares) |
Keywords
insider transaction, Form 4, ARTV, Artiva Biotherapeutics, Inc., bearish, Fred Aslan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.